Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stockGet instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Sudarshan Pharma Industries Ltd (SUDARSHAN) is currently trading at 32.57 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Sudarshan Pharma Industries Limited is a vertically integrated pharmaceutical and specialty chemicals company operating across R&D, intermediates, APIs, finished formulations and branded generics, with contract manufacturing, trading subsidiaries and an export-focused footprint spanning Asia, the Middle East, Africa and select Western markets. Financial momentum is notable: FY25 revenue reached INR 505.0 crore with EBITDA rising 75% to INR 39.9 crore and PAT improving to INR 16.0 crore, reflecting margin expansion driven by increased manufacturing sales, export ramp-up and mix improvement in resale of APIs and intermediates. Strategic expansion is evident through acquisitions (Ratna Lifesciences, Ishwari Healthcare), new subsidiaries in Singapore and Dubai, development of local Vitamin B1/B6 manufacturing, and a proposed USD 35 million FCCB — all indicating Sudarshan Pharma Industries Limited is mobilizing capital and assets to scale exports and reduce China dependency. Working capital intensity rose materially in FY25 with inventories at ~INR 140 crore, trade receivables ~INR 160 crore and short-term borrowings increasing to ~INR 160 crore, which alongside a higher debt-to-equity of 1.4x highlights Sudarshan Pharma Industries Limited's leverage and the need for disciplined cash conversion management. Market credibility is supported by a blue‑chip client list including Cipla, Dr. Reddy's, Biocon and others, and by regulatory-ready documentation (IP/BP/USP standards), positioning Sudarshan Pharma Industries Limited as a China+1 supply alternative for specialty chemicals, intermediates and selected APIs.
Over the past 52 weeks, Sudarshan Pharma Industries Ltd has traded between a low of ₹18.50 and a high of ₹35.19. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Sudarshan Pharma Industries Ltd has a market capitalization of approximately 746.52. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Sudarshan Pharma Industries Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 32.04 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 746.52 Cr, Sudarshan Pharma Industries Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Sudarshan Pharma Industries Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Sudarshan Pharma Industries Ltd is 32.04. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Investor Presentation
Q4 FY26
Investor Presentation
Q3 FY26
Investor Presentation
Q4 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Discovery themes featuring this stockDiscover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Bearish
6
Neutral
4
Bullish
4
Bearish
6
Neutral
4
Bullish
36
Bearish
0
Neutral
0
Bullish
32
Sudarshan Pharma Industries Limited is a vertically integrated pharmaceutical and specialty chemicals company operating across R&D, intermediates, APIs, finished formulations and branded generics, with contract manufacturing, trading subsidiaries and an export-focused footprint spanning Asia, the Middle East, Africa and select Western markets.
Financial momentum is notable: FY25 revenue reached INR 505.0 crore with EBITDA rising 75% to INR 39.9 crore and PAT improving to INR 16.0 crore, reflecting margin expansion driven by increased manufacturing sales, export ramp-up and mix improvement in resale of APIs and intermediates.
Strategic expansion is evident through acquisitions (Ratna Lifesciences, Ishwari Healthcare), new subsidiaries in Singapore and Dubai, development of local Vitamin B1/B6 manufacturing, and a proposed USD 35 million FCCB — all indicating Sudarshan Pharma Industries Limited is mobilizing capital and assets to scale exports and reduce China dependency.
Working capital intensity rose materially in FY25 with inventories at ~INR 140 crore, trade receivables ~INR 160 crore and short-term borrowings increasing to ~INR 160 crore, which alongside a higher debt-to-equity of 1.4x highlights Sudarshan Pharma Industries Limited's leverage and the need for disciplined cash conversion management.
Market credibility is supported by a blue‑chip client list including Cipla, Dr. Reddy's, Biocon and others, and by regulatory-ready documentation (IP/BP/USP standards), positioning Sudarshan Pharma Industries Limited as a China+1 supply alternative for specialty chemicals, intermediates and selected APIs.
Chemicals & Petrochemicals
Specialty Chemicals
784 Cr
Low Risk
33.6
42.4
0.7
4.8
35.19
18.50
Sales CAGR
Profit CAGR
ROE
ROCE
Board Meeting Preponement
The company has preponed its Board meeting from 22-May-2026 to 21-May-2026 to consider migration of equity shares from BSE SME to BSE Main and listing on NSE, and to approve a postal ballot notice and event calendar.
Listing Migration
Board meeting on 22 May 2026 to consider migrating equity shares from BSE SME to BSE main board and applying for NSE main board listing, and to approve postal ballot notice/calendar for shareholders' approval.
Listing Migration
Board to meet on 22 May 2026 to consider migrating equity shares from BSE SME to the BSE main board and applying for listing on NSE, and to approve a postal ballot to seek shareholders' approval.
FCCB issuance
Board approved issuance of up to US$20,000,000 8.00% senior unsecured foreign currency convertible bonds (FCCBs) due 2029, relevant date May 15, 2026; issue ~INR191.86 Cr; conversion ≈63,550,845 shares; board met 9:00–9:30 am.
FCCB issuance
Sudarshan Pharma's board approved issuance of up to US$20.0M 8% senior unsecured FCCBs due 2029 (opening May 18, 2026); relevant date May 15, 2026; floor price Rs.30.19 (USD1=Rs95.93) ≈ Rs191.86 Cr; ~63.55M shares on conversion; board met 9:00–9:30 AM.
Investor Presentation
Filed an updated investor presentation under Regulation 30 outlining business overview, product portfolio, a patent filing for sesamol (Apr 2026), FY25-26 export turnover (Rs21.85 Cr), FY26-27 export target (Min Rs100 Cr) and expansion plans.
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
165.65 | 821 Cr | 27.81 | 1.80 | 0.00 | 9.22 | 12.01 | 4.49 | ||
514.55 | 787 Cr | 142.29 | 2.99 | 0.00 | 2.36 | 3.43 | 1.41 | ||
875.95 | 752 Cr | 25.39 | 2.98 | 0.35 | 11.74 | 17.68 | 9.70 | ||
30.00 | 747 Cr | 32.04 | 4.81 | 0.00 | 15.03 | 12.76 | 4.61 | ||
309.00 | 738 Cr | 27.02 | 2.98 | 0.84 | 11.01 | 14.50 | 6.13 | ||
558.00 | 702 Cr | 31.37 | 5.83 | 0.26 | 18.60 | 23.77 | 14.52 | ||
292.65 | 676 Cr | 25.33 | 4.31 | 0.00 | 15.82 | 21.89 | 14.90 | ||
| Median: 7 Co. | — | 309.00 | 747 Cr | 27.81 | 2.99 | 0.00 | 11.74 | 14.50 | 6.13 |
